Clinical trials: Hypothalamic Obesity
Hypothalamic Obesity
Effects of Exenatide on Hypothalamic Obesity
The primary aim of this study is to evaluate the effect of Exenatide on weight status (change in body mass index) of children treated for craniopharyngioma that have developed hypothalamic obesity at Children's Hospitals and…
- Trial name
- NCT01061775
- Testing
- Exenatide
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Children's Hospitals and Clinics of Minnesota
Bardet-Biedl Syndrome, POMC Deficiency Obesity
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity
This is a phase 3 open-label, clinical study to evaluate the efficacy, safety and tolerability of setmelanotide over 1 year of treatment, in pediatric participants aged 2 to <6 years with obesity due to either biallelic variants…
- Conditions
- Bardet-Biedl Syndrome, POMC Deficiency Obesity, PCSK1 Deficiency Obesity, LEPR Deficiency Obesity
- Trial name
- NCT04966741
- Testing
- Setmelanotide
- Where
- 6 sites in United States, Australia and 2 more
- Volunteers
- 12 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Bardet Biedl Syndrome (BBS), Alström Syndrome (AS)
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
This pivotal, phase 3 study is designed to confirm the efficacy and safety of setmelanotide, a potent melanocortin receptor type 4 (MC4R) agonist, for the treatment of obesity and hyperphagia in participants with Bardet Biedl…
- Trial name
- NCT03746522
- Testing
- Setmelanotide
- Where
- 12 sites in United States, Canada and 4 more
- Volunteers
- 52 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Hypothalamic Obesity
Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity
The proposed multicenter study will test the effect of glucagon-like peptide (GLP)-1 agonist exenatide once weekly extended-release (ExQW, Bydureon®) on clinical outcomes and metabolic parameters in a double-blind…
- Trial name
- ECHO (NCT02664441)
- Testing
- Exenatide
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Seattle Children's Hospital
Hypothalamic Obesity
Open-Label Study of Setmelanotide in Hypothalamic Obesity
Open-label, single-arm study designed to evaluate the body weight response to setmelanotide administered subcutaneously (SC) daily in participants with hypothalamic obesity (HO).
- Trial name
- NCT04725240
- Testing
- Setmelanotide
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Obesity, Short Stature
Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children
Background: Overweight and obese children and adults often have lower levels of growth hormone in the blood. Regulation of growth hormone may be tied to weight and free fatty acids in the blood.
- Conditions
- Obesity, Short Stature, Growth Hormone Deficiency
- Trial name
- NCT01237041
- Testing
- Niacin First, Dose-Establishing Study 1 Niacin 250mg, Dose-Establishing Study 1 Niacin 500mg
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Obesity
Deep Brain Stimulation Effects on Weight Change and Metabolic Rate
This study focuses on lateral hypothalamic area (LHA) deep brain stimulation (DBS) for severe obesity. In a previous pilot study, three subjects were implanted with a DBS electrode into the LHA under an Investigational Device…
- Trial name
- NCT01933113
- Testing
- Deep Brain Stimulation of the Lateral Hypothalamic Area
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Obesity, Overweight
Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor
The purpose of this study is to determine whether exenatide can cause weight loss in patients with a history of craniopharyngioma or other brain lesion.
- Conditions
- Obesity, Overweight, Craniopharyngioma
- Trial name
- NCT01484873
- Testing
- Exenatide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Vanderbilt University Medical Center
Bardet-Biedl Syndrome, POMC Deficiency
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway
A trial to compare the weekly and daily formulations of setmelanotide in participants with genetic defects in the melanocortin-4 receptor pathway.
- Trial name
- NCT05194124
- Testing
- Setmelanotide 2 mg, Setmelanotide 2.5 mg, Setmelanotide 3 mg
- Where
- 7 sites in United States, Canada and 4 more
- Volunteers
- 19 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Hypothalamic Obesity
A Trial of Setmelanotide in Acquired Hypothalamic Obesity
The goal of this trial is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with acquired Hypothalamic Obesity (HO).
- Trial name
- NCT05774756
- Testing
- Setmelanotide
- Where
- 28 sites in United States, Canada and 4 more
- Volunteers
- 143 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Hypothalamic Injury-induced Obesity (HIO)
48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)
Double-blind, randomized, placebo-controlled, single- center study followed by an open-label extension period. The study will have two parts: Part 1: 24 weeks double-blind treatment (DB), followed by Part 2: 24 weeks open-label…
- Trial name
- NCT03845075
- Testing
- Tesofensine/Metoprolol
- Where
- Denmark
- Volunteers
- 21 people
- Sponsor
- Saniona
Gliosis, Obesity
Does What You Eat Affect Your Brain
The purpose of this study is to use magnetic resonance imaging (MRI) to evaluate the human hypothalamus for signs of inflammation in response to specific diets.
- Conditions
- Gliosis, Obesity, Eating
- Trial name
- WYE (NCT05626907)
- Testing
- Diet modification #1, Diet modification #2, Diet modification #3
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Washington
Abdominal Obesity, Growth Hormone Deficiency
Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese
Obesity, a condition that occurs when a person has too much body fat, affects about 31% of people in the United States. It is associated with increased risk of diabetes, high blood pressure, high cholesterol, and cardiovascular…
- Trial name
- NCT00675506
- Testing
- Growth hormone releasing hormone (GHRH) 1-44
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
HIV Lipodystrophy Syndrome, Growth Hormone Deficiency
Body Composition and Adipose Tissue in HIV
In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity.
- Conditions
- HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition
- Trial name
- NCT03226821
- Testing
- Tesamorelin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
Craniopharyngioma, Hypothalamic Obesity
Intranasal Oxytocin in Hypothalamic Obesity
This research study will test if oxytocin, delivered by nasal spray, will promote weight loss in children, adolescents, and adults with Hypothalamic Obesity as compared to a placebo. The study is divided into two parts.
- Trial name
- NCT02849743
- Testing
- Syntocinon
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Shana McCormack, MD